.jpg)
1 hour ago
3
Article content
(Bloomberg) — Novo Nordisk A/S agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI startup to potentially speed its development.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The startup, Cellular Intelligence, is gaining rights to the early-stage treatment and will be in charge of shepherding it through clinical trials, it said Monday. Novo, the maker of the obesity blockbuster Wegovy, stands to receive milestone payments and royalties if the program succeeds. The Danish drugmaker agreed to buy a stake in the Boston-based startup as part of the deal. No financial details were disclosed.
Article content
Article content
Article content
Cellular bid on the Parkinson’s effort after Novo last year announced it would cut its cell-therapy division to focus on lucrative areas like obesity and diabetes. The startup has opened a lab in Copenhagen and has hired many former Novo employees who previously worked on the project, according to Chief Executive Officer Micha Breakstone.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Cellular Intelligence will use its AI platform to accelerate clinical development and manufacturing, Breakstone said in an interview. The transaction marks a reversal of roles to traditional pharma deals, in which big firms typically take over products from smaller biotechs.
Article content
Cell therapies involve live cellular material that gets injected or transplanted into patients, and such treatments are approved for several types of cancer. The experimental Parkinson’s program transplants lab-grown, dopamine-producing nerve cells into the area of the brain affected by the disease using a specific device. Dopamine plays a key role in various functions including movement and mood regulation. There are no results available yet for the early clinical trial.
Article content
Article content
Cellular Intelligence plans a mid-stage study that would begin early next year. The AI will help optimize how the cells are produced, predicting how small changes affect quality and survival, Breakstone said. The data from the clinical trials will also help further refine the company’s AI models.
Article content
Novo’s commitment is a “small strategic investment” in cash, said Breakstone, a technology entrepreneur who has built and sold several AI companies before founding Cellular in 2023. The Danish company declined to elaborate.
Article content
Earlier this year, Novo struck a similar deal with Canada-based Aspect Biosystems, which acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies.
Article content
Cellular Intelligence has so far raised more than $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative, the philanthropic organization founded by Meta CEO Mark Zuckerberg.
Article content
(Updates with details on previous deal in eighth paragraph. A previous version corrected to show nerve cells, not stem cells, are transplanted)
Article content
English (US)